Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.22.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 28,096 $ 28,049 $ 33,993 $ 42,709
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 28,096 28,049 33,993 42,709
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,266 5,427 4,431 6,666
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 146 19,878 1,210 31,761
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'' )        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 137 2,375 2,034 2,595
Collaboration and License Agreements and Supply Agreements | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 547 369 1,318 1,687
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 25,000   25,000  
BMS Agreement and the 2018 BMS Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 2,266 5,427 4,431 6,666
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 240 211 484 513
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 2,026 5,216 3,947 6,153
2020 Merck Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 146 19,878 1,210 31,761
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   18,322 862 27,383
2020 Merck Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 93 705 266 1,909
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   181   412
2020 Merck Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 53 670 82 2,057
2019 EMD Serono Supply Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 137 2,375 2,034 2,595
2019 EMD Serono Supply Agreement | Contingent Payment Earned        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   2,000   2,000
2019 EMD Serono Supply Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 132 126 416 289
2019 EMD Serono Supply Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 5 249 1,618 306
Supply Agreement | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 547 369 1,318 1,687
Supply Agreement | Vaxcyte | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 542 264 1,143 469
Supply Agreement | Vaxcyte | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 5 $ 105 $ 175 $ 1,218